Gordon Campbell | Parliament TV | Parliament Today | Video | Questions Of the Day | Search


Breast and prostate cancer patients in crossfire

Breast and prostate cancer patients caught in crossfire

Breast and prostate cancer patients will be the losers if Pharmac plays off drug companies Abbot Laboratories and AstraZeneca against each other, says National’s Associate Health spokeswoman, Dr Jackie Blue.

Last week, Abbot Laboratories agreed to a 20% reduction in price and subsidy for its prostate cancer drug Lucrin, in return for Pharmac listing Abbot's arthritis drug.

Now, Pharmac has put pressure on AstraZeneca to match the 20% reduction for its drug Zoladex, which is used both in breast and prostrate cancer treatment.

AstraZeneca considers the proposition commercially unviable and has withdrawn Zoladex off the market completely.

“The real concern is that Lucrin may not be clinically equivalent to Zoladex and that this concern has not been assessed by Pharmac’s expert cancer committee,” says Dr Blue.

“If Lucrin is the last drug standing, Pharmac must give absolute assurance to the 5000 breast and prostate cancer patients diagnosed each year that Lucrin or an alternative stacks up to close scrutiny.

“While playing off the drug companies may be considered good business practice, it is not acceptable that patients end up with a possibly inferior medication, or that different patient groups are played off against each other.

“To eliminate any doubt, this matter must be sorted out by Pharmac’s expert cancer committee and they must release all submissions from expert clinicians regarding these two drugs,” says Dr Blue.


© Scoop Media

Parliament Headlines | Politics Headlines | Regional Headlines

Gordon Campbell: On The Panic In The Pacific Over China

For years, it has been no secret that China wants closer security and trade ties with the small nations of the Pacific region. All part of Beijing’s self-image as a global superpower. To that end this week, Chinese Foreign Minister Wang Yi embarked on an unprecedented 10-day tour of the Pacific, aimed at convincing his Pacific hosts to join a cross-Pacific agreement that would let Beijing provide them with high-level police training and security, shared data co-operation and other joint services ranging from agriculture to tourism...


Covid-19: Second Vaccine Booster For The Most Vulnerable
People who are at high-risk of getting very sick from a COVID-19 infection will soon be eligible to receive a second booster, COVID-19 Response Minister Chris Hipkins said today... More>>

Crime: Govt Helps Protect Shops From Ram Raids

The Government is providing further support to help Police protect small businesses affected by a spike in ram raids, Minister of Police Poto Williams says... More>>

Government: Investment Boosts Coastal Shipping In Aotearoa
New Zealand is a step closer to a more resilient, competitive, and sustainable coastal shipping sector following the selection of preferred suppliers for new and enhanced coastal shipping services, Transport Minister Michael Wood has announced today... More>>

PM Speech: Harvard University Commencement Speech - Democracy, Disinformation And Kindness

In Te Reo Māori, the language of the indigenous people of New Zealand, I paid tribute to all of the esteemed guests who stand here in this great forest of knowledge. It is a privilege to be here, and I thank you for the honour... More>>

Government: Independent Panel Appointed To Review Electoral Law
Justice Minister Kris Faafoi today announced appointments to the independent panel that will lead a review of New Zealand’s electoral law. “This panel, appointed by an independent panel of experts... More>>

Trade: Prime Minister To Visit United States
Prime Minister Jacinda Ardern is leading a trade mission to the United States this week as part of the Government’s reconnection strategy to support export growth and the return of tourists post COVID-19... More>>




InfoPages News Channels